If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can multiple tirzepatide injections be combined to make a larger dose?
Lilly does not recommend combining multiple tirzepatide injections to make a larger dose.
See important safety information, including boxed warning, in the attached prescribing information.
Combining Tirzepatide Injections
Approved Dosage Strengths
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1
Tirzepatide is a clear, colorless to slightly yellow solution available in a pre-filled, single-dose pen in 6 strengths including
- 2.5 mg/0.5 mL
- 5 mg/0.5 mL
- 7.5 mg/0.5 mL
- 10 mg/0.5 mL
- 12.5 mg/0.5 mL, and
- 15 mg/0.5 mL.1
Combining Injections
There is no information on combining multiple tirzepatide injections.
Eli Lilly and company cannot make any recommendations on combining multiple tirzepatide injections as this has not been studied in clinical trials.
Enclosed Prescribing Information
Reference
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: May 13, 2022